Viridian Therapeutics, Inc. VRDN Share-Based Payment - Unrecognized Cost of Nonvested Awards
Share-Based Payment - Unrecognized Cost of Nonvested Awards at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s share-based payment - unrecognized cost of nonvested awards.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s share-based payment - unrecognized cost of nonvested awards?
- Viridian Therapeutics, Inc. (VRDN) reported share-based payment - unrecognized cost of nonvested awards of $139.5M in Q1 2026.
- How has Viridian Therapeutics, Inc.'s share-based payment - unrecognized cost of nonvested awards changed year-over-year?
- Viridian Therapeutics, Inc.'s share-based payment - unrecognized cost of nonvested awards increased by 22.6% year-over-year, from $113.8M to $139.5M.
- What does share-based payment - unrecognized cost of nonvested awards mean?
- This represents the total compensation expense for equity-based awards that has been granted but not yet recognized in the income statement because the vesting conditions have not been met. It serves as a forward-looking indicator of future non-cash compensation expenses. Investors use this to forecast the impact of stock-based compensation on future earnings.